A player in the healthcare industry
Four of the five industrial sites located in France
Of the Group’s five bioproduction sites, four are located in France: two additional sites manufacturing plasma-derived medicinal products (Les Ulis and Lille), a cell-based recombinant protein and monoclonal antibody production site (Alès) and an industrial platform for the manufacture of advanced therapy products (Les Ulis).
A unique combination of rare know-how in bioproduction
Nearly one thousand employees working in the Group’s bioproduction departments. LFB has the rare feature of incorporating skills and know-how in various fields of biopharmaceuticals: plasma-derived medicinal products, proteins or antibodies produced by cell culture or using its rPRO™ platform, as well as advanced therapies.
Major, sustained industrial investment in France
LFB has invested over 100 million euros in its industrial capabilities within France over a period of five years, making it one of the leading industrial health companies in France.
In the highly specialised field of plasma-derived medicinal products, the new facility under construction in Arras, northern France, represents a fresh investment of some 300 million euros. In the area of biotechnology, the new production unit at the Alès site will further double LFB’s production capacity in recombinant proteins and monoclonal antibodies, particularly a recombinant coagulation factor by 2017.